According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.
Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to self-administer a non-invasive microdose.
The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism spectrum disorder (ASD), including pediatric patients. This will be the first study investigating psilocybin’s impact on children.